Global Von Willebrand Disease Treatment Market: Industry Analysis

Von Willebrand Disease Treatment Market Size – Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2029

6.12%

CAGR (2023-2029)

466.8 USD Mn.

Market Size

307

Report Pages

121

Market Tables

Overview

Global Von Willebrand Disease Treatment Market is expected to reach US$ 707.47 Mn. at a CAGR of 6.12 during the forecast period 2029.

Global Von Willebrand Disease Treatment Market Overview:

Von Willebrand Disease (vWD) is a frequent bleeding illness characterised by a deficiency or absence of von Willebrand factor (VWF), a clotting factor that aids in blood coagulation. Willebrand factor (VWF) deficiency causes severe bleeding. Type 1 vWD, Type 2 vWD, Type 3 vWD, and Acquired vWD are the four types of vWD. To know about the Research Methodology :- Request Free Sample Report

Global Von Willebrand Disease Treatment Market Dynamics:

Rising prevalence of Von Willebrand Disease is boosting the market growth

The global demand for the market has increased as governments throughout the world have become more aware of the von Willebrand treatment. The treatment for this condition varies from country to country. One of the primary factors projected to drive the growth of the acquired bleeding disorders treatment market is the rising prevalence of bleeding disorders. Another key element that may contribute to the growth of the acquired bleeding disorders treatment market is increased knowledge about genetic illnesses. Von Willebrand disease is a fairly prevalent bleeding disorder, according to the World Federation of Hemophilia. Von Willebrand disease is caused by a deficiency in the protein known as the Von Willebrand factor, which is present in the blood.

Rapid FDA approvals of vWD treatment methods and medications, as well as regional marketing approvals, are projected to propel the von Willebrand Disease (vWD) treatment industry forward in the near future. Octapharma's WILATE, a replacement medication for individuals with von Willebrand Disease, was approved by the US Food and Drug Administration (FDA) in 2015. (vWD). VEYVONDI was approved for marketing by the European Medicines Agency (EMA) in 2017 to prevent and treat von Willebrand disease. Shire plc developed VEYVONDI, a replacement therapy that was authorised by the FDA in 2015. In the near future, rapid drug approval is projected to propel the Von Willebrand Disease (vWD) Treatment Market. Because von Willebrand Disease (vWD) is such an uncommon disease, lack of awareness about the disease and its diagnosis is a major restraining factor to its growth.

The report has profiled twenty one key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Von Willebrand Disease Treatment Market Segment Analysis:

The Global Von Willebrand Disease Treatment Market is segmented on the basis of Treatment Type and Route of Administration.

Based on Treatment, the Desmopressin segment is expected to hold a dominant market share during the forecast period. Desmopressin raises FVIII by stimulating the release of VWF from cells. For patients with type 1 diabetes, which accounts for roughly 70% to 80% of cases, is considered the most preferable treatment approach.

Desmopressin is more effective for type 1 and some subtypes of type 2 von Willebrand disease than for the other types, hence it is predicted to grow during the forecast period. Furthermore, the market for von Willebrand disease treatment is expected to grow due to rising health spending and a big patient pool. This drug is offered as a nasal spray or an injection. Anti-fibrinolytic or clot-stabilizing medications are commonly used before or after a surgical treatment or tooth extraction. Adults in the age group of 18 and up are treated with replacement therapies.Based on Route of Administration, the Injection segment is anticipated to grow at a faster pace. The injection segment dominated the global von Willebrand disease treatment market in 2022. During the forecast period, the tendency is expected to continue. The injection market is projected to be driven by factors such as easy, convenient drug administration and the availability of most treatment items in injection form.

Global Von Willebrand Disease Treatment Market Regional Insights:

Global Von Willebrand Disease Treatment Market 1

North America dominates the global market.

Because of the increased desire for progressive treatment options, early adoption of new technology, and an increase in patient assistance programmes, North America is leading the industry. VWD is the most common bleeding disorder, affecting up to 1% of the US population, according to the National Hemophilia Foundation. In 2017, Versiti's BloodCenter of Wisconsin introduced a new assay for a more precise assessment of von Willebrand (VWF) factor activity. Due to rapid marketing approval of vWD therapy medications for marketing in Europe, Europe is predicted to be the second-largest market for von Willebrand Disease (vWD) treatment.

The report also helps in understanding Global Von Willebrand Disease Treatment Market dynamics, structure by analyzing the market segments and project the Global Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Market make the report investor’s guide.

Global Von Willebrand Disease Treatment Market Scope: Inquire before buying

Global Von Willebrand Disease Treatment Market
Report Coverage	Details
Base Year:	2022	Forecast Period:	2023-2029
Historical Data:	2018 to 2022	Market Size in 2022:	US $ 466.80 Mn.
Forecast Period 2023 to 2029 CAGR:	6.12%	Market Size in 2029:	US $ 707.47 Mn.
Segments Covered:	by Treatment Type	Desmopressin Replacement Therapies Clot-stabilizing Medications Others
	by Route of Administration	Oral Injection Other

Global Von Willebrand Disease Treatment Market, By Region:

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Global Von Willebrand Disease Treatment Market, Key players:

1. Octapharma AG
2. Grifols, S.A.
3. Shire plc
4. Bayer AG
5. CSL Behring
6. Pfizer, Inc.
7. Akorn, Inc.
8. Ferring B.V.
9. Kyowa Kirin Co., Ltd
10.Baxter
11.Novo Nordisk A/S
12.Bayer AG
13.Sanofi
14.Heritage
15.Teva Pharmaceutical Industries Ltd
16.Glenmark Pharmaceuticals Ltd
17.Bausch Health
18.Amneal Pharmaceuticals LLC
19.Sun Pharmaceutical Industries Ltd
20.Mylan N.V.
21.Zydus Cadila

FAQ
1] What segments are covered in the Global Von Willebrand Disease Treatment Market report?
Ans. The segments covered in the Global Market report are based on Treatment Type, Route of Administration.

2] Which region is expected to hold the highest share in the Global Von Willebrand Disease Treatment Market?
Ans. North America region is expected to hold the highest share in the Global Market.

3] What is the market size of the Global Market by 2029?
Ans. The market size of the Global Market by 2029 is expected to reach US$ 707.47 Mn.

4] What is the forecast period for the Global Market?
Ans. The forecast period for the Global Market is 2023-2029.

5] What was the market size of the Global Market in 2022?
Ans. The market size of the Global Market in 2022 was valued at US$ 466.80 Mn.

1. Von Willebrand Disease Treatment Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Von Willebrand Disease Treatment Market: Dynamics 2.1. Von Willebrand Disease Treatment Market Trends by Region 2.1.1. North America Von Willebrand Disease Treatment Market Trends 2.1.2. Europe Von Willebrand Disease Treatment Market Trends 2.1.3. Asia Pacific Von Willebrand Disease Treatment Market Trends 2.1.4. Middle East and Africa Von Willebrand Disease Treatment Market Trends 2.1.5. South America Von Willebrand Disease Treatment Market Trends 2.2. Von Willebrand Disease Treatment Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Von Willebrand Disease Treatment Market Drivers 2.2.1.2. North America Von Willebrand Disease Treatment Market Restraints 2.2.1.3. North America Von Willebrand Disease Treatment Market Opportunities 2.2.1.4. North America Von Willebrand Disease Treatment Market Challenges 2.2.2. Europe 2.2.2.1. Europe Von Willebrand Disease Treatment Market Drivers 2.2.2.2. Europe Von Willebrand Disease Treatment Market Restraints 2.2.2.3. Europe Von Willebrand Disease Treatment Market Opportunities 2.2.2.4. Europe Von Willebrand Disease Treatment Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Von Willebrand Disease Treatment Market Drivers 2.2.3.2. Asia Pacific Von Willebrand Disease Treatment Market Restraints 2.2.3.3. Asia Pacific Von Willebrand Disease Treatment Market Opportunities 2.2.3.4. Asia Pacific Von Willebrand Disease Treatment Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Von Willebrand Disease Treatment Market Drivers 2.2.4.2. Middle East and Africa Von Willebrand Disease Treatment Market Restraints 2.2.4.3. Middle East and Africa Von Willebrand Disease Treatment Market Opportunities 2.2.4.4. Middle East and Africa Von Willebrand Disease Treatment Market Challenges 2.2.5. South America 2.2.5.1. South America Von Willebrand Disease Treatment Market Drivers 2.2.5.2. South America Von Willebrand Disease Treatment Market Restraints 2.2.5.3. South America Von Willebrand Disease Treatment Market Opportunities 2.2.5.4. South America Von Willebrand Disease Treatment Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Von Willebrand Disease Treatment Industry 2.8. Analysis of Government Schemes and Initiatives For Von Willebrand Disease Treatment Industry 2.9. Von Willebrand Disease Treatment Market Trade Analysis 2.10. The Global Pandemic Impact on Von Willebrand Disease Treatment Market 3. Von Willebrand Disease Treatment Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2022-2029 3.1. Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 3.1.1. Desmopressin 3.1.2. Replacement Therapies 3.1.3. Clot-stabilizing Medications 3.1.4. Others 3.2. Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 3.2.1. Oral 3.2.2. Injection 3.2.3. Other 3.3. Von Willebrand Disease Treatment Market Size and Forecast, by Region (2022-2029) 3.3.1. North America 3.3.2. Europe 3.3.3. Asia Pacific 3.3.4. Middle East and Africa 3.3.5. South America 4. North America Von Willebrand Disease Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 4.1. North America Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 4.1.1. Desmopressin 4.1.2. Replacement Therapies 4.1.3. Clot-stabilizing Medications 4.1.4. Others 4.2. North America Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 4.2.1. Oral 4.2.2. Injection 4.2.3. Other 4.3. North America Von Willebrand Disease Treatment Market Size and Forecast, by Country (2022-2029) 4.3.1. United States 4.3.1.1. United States Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 4.3.1.1.1. Desmopressin 4.3.1.1.2. Replacement Therapies 4.3.1.1.3. Clot-stabilizing Medications 4.3.1.1.4. Others 4.3.1.2. United States Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 4.3.1.2.1. Oral 4.3.1.2.2. Injection 4.3.1.2.3. Other 4.3.2. Canada 4.3.2.1. Canada Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 4.3.2.1.1. Desmopressin 4.3.2.1.2. Replacement Therapies 4.3.2.1.3. Clot-stabilizing Medications 4.3.2.1.4. Others 4.3.2.2. Canada Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 4.3.2.2.1. Oral 4.3.2.2.2. Injection 4.3.2.2.3. Other 4.3.3. Mexico 4.3.3.1. Mexico Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 4.3.3.1.1. Desmopressin 4.3.3.1.2. Replacement Therapies 4.3.3.1.3. Clot-stabilizing Medications 4.3.3.1.4. Others 4.3.3.2. Mexico Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 4.3.3.2.1. Oral 4.3.3.2.2. Injection 4.3.3.2.3. Other 5. Europe Von Willebrand Disease Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 5.1. Europe Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 5.2. Europe Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 5.3. Europe Von Willebrand Disease Treatment Market Size and Forecast, by Country (2022-2029) 5.3.1. United Kingdom 5.3.1.1. United Kingdom Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 5.3.1.2. United Kingdom Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 5.3.2. France 5.3.2.1. France Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 5.3.2.2. France Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 5.3.3. Germany 5.3.3.1. Germany Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 5.3.3.2. Germany Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 5.3.4. Italy 5.3.4.1. Italy Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 5.3.4.2. Italy Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 5.3.5. Spain 5.3.5.1. Spain Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 5.3.5.2. Spain Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 5.3.6. Sweden 5.3.6.1. Sweden Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 5.3.6.2. Sweden Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 5.3.7. Austria 5.3.7.1. Austria Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 5.3.7.2. Austria Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 5.3.8. Rest of Europe 5.3.8.1. Rest of Europe Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 5.3.8.2. Rest of Europe Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6. Asia Pacific Von Willebrand Disease Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 6.1. Asia Pacific Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 6.2. Asia Pacific Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.3. Asia Pacific Von Willebrand Disease Treatment Market Size and Forecast, by Country (2022-2029) 6.3.1. China 6.3.1.1. China Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 6.3.1.2. China Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.3.2. S Korea 6.3.2.1. S Korea Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 6.3.2.2. S Korea Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.3.3. Japan 6.3.3.1. Japan Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 6.3.3.2. Japan Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.3.4. India 6.3.4.1. India Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 6.3.4.2. India Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.3.5. Australia 6.3.5.1. Australia Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 6.3.5.2. Australia Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.3.6. Indonesia 6.3.6.1. Indonesia Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 6.3.6.2. Indonesia Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.3.7. Malaysia 6.3.7.1. Malaysia Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 6.3.7.2. Malaysia Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.3.8. Vietnam 6.3.8.1. Vietnam Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 6.3.8.2. Vietnam Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.3.9. Taiwan 6.3.9.1. Taiwan Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 6.3.9.2. Taiwan Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 6.3.10. Rest of Asia Pacific 6.3.10.1. Rest of Asia Pacific Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 6.3.10.2. Rest of Asia Pacific Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 7. Middle East and Africa Von Willebrand Disease Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 7.1. Middle East and Africa Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 7.2. Middle East and Africa Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 7.3. Middle East and Africa Von Willebrand Disease Treatment Market Size and Forecast, by Country (2022-2029) 7.3.1. South Africa 7.3.1.1. South Africa Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 7.3.1.2. South Africa Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 7.3.2. GCC 7.3.2.1. GCC Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 7.3.2.2. GCC Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 7.3.3. Nigeria 7.3.3.1. Nigeria Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 7.3.3.2. Nigeria Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 7.3.4. Rest of ME&A 7.3.4.1. Rest of ME&A Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 7.3.4.2. Rest of ME&A Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 8. South America Von Willebrand Disease Treatment Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 8.1. South America Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 8.2. South America Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 8.3. South America Von Willebrand Disease Treatment Market Size and Forecast, by Country (2022-2029) 8.3.1. Brazil 8.3.1.1. Brazil Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 8.3.1.2. Brazil Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 8.3.2. Argentina 8.3.2.1. Argentina Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 8.3.2.2. Argentina Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 8.3.3. Rest Of South America 8.3.3.1. Rest Of South America Von Willebrand Disease Treatment Market Size and Forecast, by Treatment Type (2022-2029) 8.3.3.2. Rest Of South America Von Willebrand Disease Treatment Market Size and Forecast, by Route of Administration (2022-2029) 9. Global Von Willebrand Disease Treatment Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Von Willebrand Disease Treatment Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Octapharma AG 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Grifols, S.A. 10.3. Shire plc 10.4. Bayer AG 10.5. CSL Behring 10.6. Pfizer, Inc. 10.7. Akorn, Inc. 10.8. Ferring B.V. 10.9. Kyowa Kirin Co., Ltd 10.10. Baxter 10.11. Novo Nordisk A/S 10.12. Bayer AG 10.13. Sanofi 10.14. Heritage 10.15. Teva Pharmaceutical Industries Ltd 10.16. Glenmark Pharmaceuticals Ltd 10.17. Bausch Health 10.18. Amneal Pharmaceuticals LLC 10.19. Sun Pharmaceutical Industries Ltd 10.20. Mylan N.V. 10.21. Zydus Cadila 11. Key Findings 12. Industry Recommendations 13. Von Willebrand Disease Treatment Market: Research Methodology 14. Terms and Glossary

Global Von Willebrand Disease Treatment Market